1. Antihypertensive agent losartan promotes tongue squamous cell carcinoma cell proliferation via EGFR/ERK1/2/cyclin D1 signaling axis.
- Author
-
Wu LY, Su BC, Yu HH, Cheng CC, Tsai CC, Hsu PL, and Lee CW
- Subjects
- Humans, Cell Line, Tumor, Apoptosis drug effects, MAP Kinase Signaling System drug effects, Signal Transduction drug effects, Blotting, Western, Angiotensin II Type 1 Receptor Blockers pharmacology, Losartan pharmacology, Tongue Neoplasms drug therapy, Tongue Neoplasms pathology, Tongue Neoplasms metabolism, Cell Proliferation drug effects, ErbB Receptors metabolism, Cyclin D1 metabolism, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell metabolism, Antihypertensive Agents pharmacology
- Abstract
Objective: To study the effects of losartan, an angiotensin II receptor blocker, in the SCC4 and SCC25 human tongue squamous cell carcinoma cell lines., Methods: Cell proliferation was measured by MTS/PMS activity and trypan blue exclusion assays. The levels of the cell proliferation marker, cyclin D1, were analyzed by western blotting. Apoptosis was assessed by caspase-3 activation and Annexin V-FITC/propidium iodide double staining. Activation of epidermal growth factor receptor (EGFR) and ERK1/2 was validated by western blotting., Results: Moderate concentrations of losartan enhanced the proliferation of SCC4 and SCC25 cells. However, high losartan concentrations induced apoptosis in SCC4 cells. Losartan activated the EGFR/ERK1/2/cyclin D1 signaling axis, which in turn promoted cell proliferation. Afatinib (EGFR inhibitor) and U0126 (ERK1/2 inhibitor) abolished losartan-induced cell proliferation. In contrast, UC2288 (p21 inhibitor) enhanced it., Conclusions: Losartan exhibited dual effects on tongue squamous cell carcinoma cells. Moderate losartan concentrations facilitated cell proliferation, whereas high concentrations induced cytotoxicity in tongue carcinoma cells., Competing Interests: Declaration of competing interest The authors declare that they have no competing interest for this article., (Copyright © 2024 Japanese Association for Oral Biology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF